July 8, 2020 / 5:53 AM / a month ago

BRIEF-Valbiotis To Launch Phase II/III REVERSE-IT Clinical Study On TOTUM-63

July 8 (Reuters) - VALBIOTIS SA:

* VALBIOTIS: AUTHORIZATION TO LAUNCH THE INTERNATIONAL PHASE II/III REVERSE-IT CLINICAL STUDY ON TOTUM-63, TO REDUCE TYPE 2 DIABETES RISK FACTORS

* THIS PHASE II/III STUDY, HAS BEEN DESIGNED JOINTLY WITH NESTLÉ HEALTH SCIENCE’S TEAMS AS PART OF GLOBAL STRATEGIC PARTNERSHIP

* FAVOURABLE OPINION FROM FRENCH ETHICAL COMMITTEE (CPP) AND AUTHORIZATION FROM FRENCH NATIONAL AGENCY FOR SAFETY OF MEDICINES AND HEALTH PRODUCTS (ANSM)

* INTERNATIONAL STUDY WILL INCLUDE 600 SUBJECTS WITH ALTERED GLUCOSE METABOLISM, SPANNING FROM ELEVATED FASTING GLYCEMIA TO EARLY, YET UNTREATED, TYPE 2 DIABETES. ITS PRIMARY ENDPOINT IS FASTING GLYCEMIA Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below